drugset / Trial / NCT02124525

N-acetylcysteine for Tobacco Smoking

NCT02124525

Phase 3 Unknown 32 enrolled State University of Londrina
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to investigate the efficacy of N-acetylcysteine (NAC) for smoking cessation in a double blind, randomized, placebo-controlled trial. Simultaneously, the study aims to elucidate the role of inflammatory markers and oxidative stress related to nicotine addiction and the use of NAC, an acetylated precursor of cysteine, a naturally occurring amino acid that has antioxidant actions in its own right, in reducing oxidative stress and inflammation in smokers. It will evaluate the use of NAC in smoking cessation, after 4, 8 and 12 weeks of treatment.

Timeline

Start
2013-02
Primary completion
2014-04
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator N-acetylcysteine Small molecule 1500 mg